Research Article

Phase I Trial of Intra-arterial Administration of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Multiple System Atrophy

Table 3

Longitudinal changes in UMSARS scores.

Low-dose groupMedium- and high-dose groupsOverall valuePost hoc valuea

UMSARS part I
 V1 (-1 month)20.00 (1.74)17.50 (1.23)Group: 0.1840.418
 V7 (+1 month)19.67 (2.05)18.67 (1.45)Time: 0.0200.613
 V8 (+3 months)26.67 (3.13)20.17 (2.21): 0.2370.401
UMSARS part II
 V1 (-1 month)20.33 (1.73)18.00 (1.22)Group: 0.1650.458
 V7 (+1 month)20.33 (2.95)17.50 (2.08)Time: 0.0490.458
 V8 (+3 months)25.33 (2.39)18.33 (1.69): 0.1310.144
Total UMSARS
 V1 (-1 month)43.00 (2.79)37.67 (1.97)Group: 0.1110.244
 V7 (+1 month)42.67 (4.46)38.33 (3.16)Time: 0.0080.454
 V8 (+3 months)55.33 (5.14)40.83 (3.64): 0.0960.165

Values are expressed as estimated mean (standard error). Abbreviations: UMSARS: Unified Multiple System Atrophy Rating Scale; MSC: mesenchymal stem cell. aFalse discovery rate (FDR) adjusted value.